STOCK TITAN

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Oragenics announced a webinar on neurotrauma medicine to be held on May 20, 2024, at 12:00 PM ET. The webinar will focus on Traumatic Brain Injury (TBI), its causes, and its links to long-term neurological disorders. The company will discuss their lead drug candidate, ONP-002, a neurosteroid for mild TBI, and present outcomes from preclinical and Phase I trials. Details of the forthcoming Phase II trial in acute and emergency departments will also be covered. Expert speakers include Dr. James P. Kelly and Dr. Frank Peacock IV.

Positive
  • Oragenics is addressing an unmet medical need in Traumatic Brain Injury (TBI).
  • Upcoming Phase II clinical trial for ONP-002 indicates ongoing research and development.
  • Webinar provides visibility and engagement with the medical community.
  • Presentation of preclinical and Phase I trial results for ONP-002 shows progress.
Negative
  • No mention of revenue or financial performance in the press release.
  • Upcoming Phase II trial suggests that ONP-002 is still in relatively early stages of development.
  • Potential risks associated with clinical trial outcomes and drug approval processes.

SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET.

The discussion will address the unmet medical need in Traumatic Brain Injury (TBI), commonly known as concussion, explore common causes, and examine its association with other long-term neurological disorders. Additionally, the company will present its lead drug candidate, ONP-002, an innovative neurosteroid designed to treat mild TBI and discuss its outcomes from preclinical and Phase I trials, as well as details of an upcoming Phase II clinical trial to be conducted in acute and emergency departments. Details for the webinar are as follows:

Webinar Topic: Neurotrauma Medicine
When: Monday, May 20, 2024
Time: 12:00 PM Eastern Time
Register: Webinar Link
Speakers: 

  • James P. Kelly, MA, MD, FAAN, FANA, Emeritus Professor of Neurology and PM&R, University of Colorado School of Medicine
  • Frank Peacock, IV, MD, FACEP, FACC, FESC, Vice Chair for Emergency Medicine Research, Baylor College of Medicine

About Oragenics, Inc.
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.

Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the ability of the Company to timely and successfully undertake Phase II clinical trials using its novel drug-device combination for the treatment of mild Traumatic Brain Injury. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: the Company’s ability to advance the development of its product candidates, including the neurology assets, under the timelines and in accord with the milestones it projects; the Company’s ability to raise capital and obtain funding, non-dilutive or otherwise, for the development of its product candidates; the regulatory application process, research and development stages, and future clinical data and analysis relating to its product candidates, including any meetings, decisions by regulatory authorities, such as the FDA and investigational review boards, whether favorable or unfavorable; the Company’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the nature of competition and development relating to concussion treatments; the Company’s expectations as to the outcome of preclinical studies and clinical trials and the potential benefits, activity, effectiveness and safety of its product candidates including as to administration, transmission, manufacturing, storage and distribution; and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth is as of the date hereof unless otherwise indicated. You should consider these factors in evaluating the forward-looking statements included and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

Oragenics, Inc.
Janet Huffman, Chief Financial Officer
813-286-7900
jhuffman@oragenics.com


FAQ

What is the topic of Oragenics' upcoming webinar?

The webinar will focus on Neurotrauma Medicine, specifically addressing Traumatic Brain Injury (TBI).

When is Oragenics hosting its Neurotrauma Medicine webinar?

The webinar is scheduled for May 20, 2024, at 12:00 PM ET.

What will Oragenics discuss during the webinar?

Oragenics will discuss the unmet medical need in TBI, present their lead drug candidate ONP-002, and share outcomes from preclinical and Phase I trials.

Who are the speakers for Oragenics' Neurotrauma Medicine webinar?

The speakers are Dr. James P. Kelly and Dr. Frank Peacock IV.

What is ONP-002?

ONP-002 is Oragenics' lead drug candidate, a neurosteroid designed to treat mild Traumatic Brain Injury (TBI).

What phase of clinical trials will ONP-002 be entering?

ONP-002 will be entering a Phase II clinical trial focused on acute and emergency departments.

Oragenics Inc.

NYSE:OGEN

OGEN Rankings

OGEN Latest News

OGEN Stock Data

4.62M
9.71M
25.41%
11.13%
1.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SARASOTA